Natco Pharma Names Senior Leadership for Analytical and Formulation Research & Development
Natco Pharma Limited has announced senior management designations, effective July 6, 2026, positioning two key individuals within its research divisions. Mr. Gnanadeva Chalapathy Gudipati has been designated as Senior Vice President of Analytical Research & Development, while Mr. Madhava Rao Karicherla has been appointed as Vice President of Formulation Research & Development, Pharma Division, Kothur Unit.These appointments bolster the company’s capabilities in complex pharmaceutical research and development, bringing together specialized experience in analytical methods and formulation sciences.
The designated officials bring extensive profiles to their new roles. Mr. Gnanadeva Chalapathy Gudipati has been appointed Senior Vice President - Analytical Research & Development. His profile includes rich experience in resolving complex technical problems using scientific innovation and project management. He is credited with successfully developing a Complex injectable portfolio for the organization by developing sophisticated analytical methods and validating them.
Mr. Madhava Rao Karicherla has been designated as Vice President - Formulation Research & Development, Pharma Division, Kothur Unit. Mr. Karicherla possesses extensive experience in global Generic product development, operations management, and quality assurance within the pharmaceutical industry. His expertise covers Pre-formulation and formulation development of various dosage forms including immediate release tablets, extended release tablets, dry capsule formulations, liquid orals, and parenteral dosage forms.
Details regarding both individuals’ professional backgrounds are summarized below:
| Particulars | Mr. Gnanadeva Chalapathy Gudipati | Mr. Madhava Rao Karicherla |
|---|---|---|
| Designation | Senior Vice President - Analytical Research & Development | Vice President - Formulation Research & Development, Pharma Division, Kothur Unit |
| Date of Appointment | July 6, 2026 | July 6, 2026 |
| Brief Profile | Has rich experience in resolving complex technical problems using scientific innovation, project management, and leadership. He successfully developed a Complex injectable portfolio through the development and validation of complex analytical methods. | An innovative and performance-driven Pharmaceutical professional with over 20 years of experience in global Generic product development and operations management. |
| Experience Notes | Exposure includes technical due diligence, Internal and External audits, technical write ups and out licensing. | Possesses expertise in Pre-formulation and formulation development for various dosage forms. He has been associated with Natco Pharma Limited since September 15, 2017, and since November 15, 2024 (prior roles included Mylan Laboratories Limited and Sandoz India Private Limited). |
NATCOPHARM Stock Price Movement
Shares of Natco Pharma Limited closed today, shedding 0.34% to settle at ₹932 as the market session concluded. The stock traded during the day within a range defined by a low of ₹919.9 and a high of ₹941.4.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: